Related Experiment Video
Updated: Jul 2, 2026
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Immunotherapy of type 1 diabetes
Li Li1, Zuoan Yi, Roland Tisch
1Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7290, USA.
Archivum Immunologiae Et Therapiae Experimentalis
|August 30, 2008
Summary
Type 1 diabetes (T1D) involves autoimmune destruction of insulin-producing cells. This review explores antigen- and antibody-based immunotherapies as potential treatments, evaluating their pros and cons.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Type 1 diabetes (T1D) is an autoimmune condition characterized by the destruction of insulin-producing beta cells.
- Current management involves daily insulin injections to control hyperglycemia, but this is not a cure.
- Significant research is dedicated to developing immunotherapies for T1D prevention and treatment.
Purpose of the Study:
- To review and analyze antigen- and antibody-based immunotherapy approaches for Type 1 diabetes.
- To discuss the strengths and weaknesses of these different immunotherapy strategies.
- To provide insights into the clinical potential of immunotherapies for T1D.
Main Methods:
- Literature review of antigen-based immunotherapies for T1D.
- Literature review of antibody-based immunotherapies for T1D.
- Comparative analysis of the efficacy and safety profiles of discussed approaches.
Main Results:
- Antigen-based immunotherapies aim to re-establish immune tolerance to beta cell antigens.
- Antibody-based immunotherapies target specific immune cells or signaling pathways involved in beta cell destruction.
- Both approaches present unique advantages and challenges in preclinical and clinical settings.
Conclusions:
- Immunotherapies hold promise for preventing and treating Type 1 diabetes.
- Careful consideration of antigen- and antibody-based strategies is crucial for therapeutic development.
- Further research is needed to optimize these immunotherapies for widespread clinical application.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...